|Bid||31.00 x 800|
|Ask||47.90 x 1000|
|Day's Range||47.16 - 47.91|
|52 Week Range||37.69 - 50.69|
|Beta (5Y Monthly)||-0.07|
|PE Ratio (TTM)||30.04|
|Forward Dividend & Yield||0.73 (1.52%)|
|Ex-Dividend Date||Oct 02, 2019|
|1y Target Est||52.57|
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, is excited to announce the publication of results from a new randomised controlled trial (RCT) demonstrating that the use of PICO◊ Single Use Negative Pressure Wound Therapy System (sNPWT) significantly reduced wound area, depth and volume compared with traditional negative pressure wound therapy (tNPWT) in patients with venous leg ulcers (VLUs) and diabetic foot ulcers (DFUs).1*
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology business, today announces the publication of a new randomized controlled trial (RCT) which demonstrated that the use of PICO Single Use Negative Pressure Wound Therapy System (sNPWT) significantly reduced wound area, depth and volume compared to traditional negative pressure wound therapy (tNPWT) in patients with lower extremity ulcers.1*
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]
Today we'll look at Smith & Nephew plc (LON:SN.) and reflect on its potential as an investment. Specifically, we're...
The 700+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the third quarter, which unveil their equity positions as of September 30. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, is pleased to announce the completion of the first surgeries utilizing its new JOURNEY II Unicompartmental Knee (UK) System. Built on the heritage of the most clinically successful partial knee,1,2 JOURNEY II UK is designed to help patients rediscover their normal life before they first experienced knee pain.
As every investor would know, you don't hit a homerun every time you swing. But it's not unreasonable to try to avoid...
LONDON , Nov. 19, 2019 /PRNewswire/ -- Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology business, today announces a new clinical study illustrating the successful treatment of large (3-5cm) ...
OXINIUM Technology is the first advanced bearing material available to support modular dual mobility throughout the entire offering LONDON , Nov. 8, 2019 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), ...
TUCSON, Ariz., Nov. 4, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (AXDX) today announced that Roland Diggelmann has been appointed to its Board of Directors. "On behalf of the entire board, I am delighted to welcome Roland to Accelerate Diagnostics," commented John Patience, Chairman of the Board of Directors. "Roland brings extensive experience from his decades of successful diagnostics company leadership.
A federal appeals court on Thursday said the structure of the U.S. Patent Trial and Appeal Board is unconstitutional, but the problem can be fixed by severing a portion of federal patent law that restricts the removal of administrative patent judges. The U.S. Federal Circuit Court of Appeals said the impact of its decision would be "limited" to cases in which the board had issued final written decisions, and litigants challenged on appeal the appointment of the board's judges under the U.S. Constitution's Appointments Clause.
European shares broke a three-day run of losses on Monday, as investors stuck to hopes that Britain will avoid a disorderly exit from the European Union, while positive corporate updates and comments on U.S.-China trade talks added to the upbeat mood. The pan-European STOXX 600 index ended the session 0.6% higher, barely budging on news House of Commons speaker John Bercow refused to allow a vote on Prime Minister Boris Johnson's Brexit divorce deal, saying the same issue had been discussed on Saturday.
When we invest, we're generally looking for stocks that outperform the market average. Buying under-rated businesses...
The former chief business officer of U.S. biotechnology company Osiris Therapeutics Inc has agreed to pay a $40,000 civil penalty for lying to auditors, the Securities and Exchange Commission said on Thursday. The SEC had alleged that Bobby Dwayne Montgomery prompted Osiris to book fake revenue and give false information to auditors. Montgomery agreed to a judgment that enjoins him from future violations of securities law, the SEC said in a statement.
We at Insider Monkey have gone over 730 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of June 28th. In this article, we look at what those funds think of Smith & Nephew plc (NYSE:SNN) based on […]